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Initial experience of dedicated breast PET imaging of ER+
breast cancers using [F-18]fluoroestradiol
Ella F. Jones1, Kimberly M. Ray1, Wen Li1, Amy J. Chien2, Rita A. Mukhtar3, Laura J. Esserman3, Benjamin L. Franc1, Youngho Seo1,
Miguel H. Pampaloni1, Bonnie N. Joe1 and Nola M. Hylton1
Dedicated breast positron emission tomography (dbPET) is an emerging technology with high sensitivity and spatial resolution that
enables detection of sub-centimeter lesions and depiction of intratumoral heterogeneity. In this study, we report our initial
experience with dbPET using [F-18]fluoroestradiol (FES) in assessing ER+ primary breast cancers. Six patients with >90% ER+ and
HER2− breast cancers were imaged with dbPET and breast MRI. Two patients had ILC, three had IDC, and one had an unknown
primary tumor. One ILC patient was treated with letrozole, and another patient with IDC was treated with neoadjuvant
chemotherapy without endocrine treatment. In this small cohort, we observed FES uptake in ER+ primary breast tumors with
specificity to ER demonstrated in a case with tamoxifen blockade. FES uptake in ILC had a diffused pattern compared to the distinct
circumscribed pattern in IDC. In evaluating treatment response, the reduction of SUVmax was observed with residual disease in an
ILC patient treated with letrozole, and an IDC patient treated with chemotherapy. Future study is critical to understand the change
in FES SUVmax after endocrine therapy and to consider other tracer uptake metrics with SUVmax to describe ER-rich breast cancer.
Limitations include variations of FES uptake in different ER+ breast cancer diseases and exclusion of posterior tissues and axillary
regions. However, FES-dbPET has a high potential for clinical utility, especially in measuring response to neoadjuvant endocrine
treatment. Further development to improve the field of view and studies with a larger cohort of ER+ breast cancer patients are
warranted.
npj Breast Cancer            (2019) 5:12 ; https://doi.org/10.1038/s41523-019-0107-9
INTRODUCTION
Advances in our understanding of breast cancer biology have
provided an improved ability to provide patients with prognostic
information and treat their disease with precisely targeted therapy
regimens. One of the most dramatic of these advances has been
in endocrine therapy whereby the estrogen-based signaling for
tumor growth is interrupted in estrogen receptor positive (ER+)
breast cancer patients. For over three decades, clinical evidence
has suggested that ER+ tumors are responsive to endocrine
treatment.1,2 However, not all ER+ tumors derive the same benefit
from endocrine therapy, and some patients with ER+ breast
cancer will have improved outcomes with additional systemic
therapy such as chemotherapy. Genomic assays such as Oncotype
DX™ (Genomic Health, CA, USA)3,4 and MammaPrint™ (Agendia BV,
The Netherlands)5,6 can help identify which patients can be safely
treated without chemotherapy and estimate the potential benefit
of chemotherapy. Despite this, there is still uncertainty in the
management of many women with ER+ breast cancer.
Intratumoral heterogeneity of ER expression in some breast
tumors poses a dilemma; sampling by biopsy may produce
varying results with different outcomes in overall tumor assess-
ment.7 In vivo non-invasive whole-tumor assessment could
theoretically decrease the uncertainty associated with biopsy
sampling. Non-invasive molecular imaging has served as an
in vivo assay to assess for distant disease in breast cancer patients,
and [18F]fluorodeoxyglucose (FDG) positron emission tomography
(PET) imaging plays a crucial role in evaluating for metastatic
disease in breast cancer staging. In assessing primary tumors,
however, the standard whole-body PET/CT is hampered by limited
spatial resolution that results in significant partial volume effect
that complicates quantification of small lesions. In addition, when
whole-body PET/CT is performed with the patient in a supine
position, the breast volume is naturally collapsed and depiction of
the primary tumor is not ideal. Dedicated breast PET (dbPET) is an
emerging PET technology specially designed for breast imaging.
Compared to the whole-body PET/CT using FDG as a tracer, dbPET
with the patient in a prone position has demonstrated a higher
sensitivity8 to detect sub-centimeter lesions and a higher spatial
resolution to depict intratumoral heterogeneity9 in clinical studies.
In our own work, we have also demonstrated the use of dbPET
with FDG to evaluate the primary tumors in a breast cancer
patient. At high sensitivity, dbPET can capture the early response
to neoadjuvant chemotherapy in primary tumors and reveal
functional changes that precede anatomic changes at magnetic
resonance imaging (MRI).10
In addition to evaluating tumor glucose metabolism by FDG,
PET offers other functional information by the use of ligands
labeled with positron-emitting radionuclides. Estradiol, a form of
estrogen, is a potent agonist for ER. 18F-fluoroestradiol (FES) has
been developed specifically to image ER expression in breast
cancers.11,12 Recent clinical studies have shown that FES-PET has a
high overall sensitivity (84%) and specificity (98%) in assessing the
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ER status in breast cancers,13 and FES uptake has clear potential to
guide therapy selection and to predict endocrine treatment
response.14 In this study, we further evaluate the use of the dbPET
with FES to assess the ER expression and its change in response to
treatment in the ER+ breast cancer subtype.
RESULTS
Primary tumor characterization
Six patients diagnosed with >90% ER+ and human epidermal
growth factor receptor-2 negative (HER2−) breast cancer by
immunohistochemistry (IHC) and fluorescence in situ hybridization
(FISH) were imaged. Patient and tumor characteristics are
summarized in Table 1, and the FES-dbPET imaging results are
summarized in Table 2. Patient ages ranged from 33 to 64.
Patients #1 and 2 had infiltrating invasive lobular carcinomas (ILC)
with no lymphadenopathy or distant metastasis by ultrasound or
bone scan. Their tumor measured respectively up to 6.7 and
5.3 cm by dynamic contrast-enhanced MRI (DCE-MRI). Their
corresponding maximum FES standardized uptake value (SUVmax)
was 15.83 and 22.42 with total FES uptake volume at 15.72 and
35.63 cm3, respectively (Fig. 1a–d). The remaining patients were
presented with locally advanced diseases, three with invasive
ductal carcinomas (IDC) and one with an unknown primary tumor.
No lymphadenopathy or distant metastasis was noted in IDC
patients by whole-body FDG-PET/CT or clinical exams. Patient #3
had a primary tumor measuring 2.8 cm by DCE-MRI and SUVmax of
6.44 by whole-body FDG-PET/CT. The primary ER+ tumor was re-
demonstrated with FES-dbPET SUVmax at 13.02 and total uptake
volume at 12.60 cm3. The MRI of patient #4 showed a 0.9 cm IDC
and a 1.3 cm irregular mass. Her FES-dbPET showed an SUVmax at
7.44 (uptake volume of 0.22 cm3) corresponding to the 0.9 cm
anterior mass but the more posterior disease foci seen on MRI
were excluded from the field of view of dbPET (Fig. 1e, f). Patient
#5 demonstrated the absence of FES uptake in her 3.4 cm IDC,
which was due to estrogen receptor blockade from recent
administration of tamoxifen for a fertility preservation procedure
(Fig. 1g, h). The final patient (#6) had metastatic cervical and
axillary lymphadenopathy secondary to a breast primary that was
occult on mammography and MRI. Her whole-body FDG-PET/CT
showed multiple hypermetabolic cervical lymph nodes measuring
up to 2.2 cm with SUVmax of 6.0 and axillary lymph nodes
measuring up to 2.7 cm with SUVmax of 4.5. Her bilateral breast
tissues were heterogeneously FDG-avid with no hypermetabolic
mass. FES-dbPET also showed no corresponding uptake in the
breast bilaterally.
Treatment response assessment
FES-dbPET was also used to monitor treatment response in Patient
#1 and # 3. Patient #1 was imaged after 2 months of neoadjuvant
endocrine therapy (inhibition of estrogen production with letrozole).
Her FES uptake measured by SUVmax decreased from 15.83 to 6.11
and total uptake volume reduced from 15.72 to 0.37 cm3. Her follow-
up DCE-MRI showed tumor reduction in the extent of non-mass
enhancement with significant background enhancement (Fig. 2a–c).
Surgical pathology showed 5 cm of residual ILC with Ki67 of <1%
(reduced from 30% at pre-treatment) and tumor cellularity of 25%
(pre-treatment cellularity not available).
Patient #3 participated in a neoadjuvant treatment trial and was
treated with neoadjuvant chemotherapy without endocrine
therapy. After three weekly cycles, her total FES uptake volume
dropped from 12.60 to 8.73 cm3. Her DCE-MRI at the correspond-
ing time point also confirmed a reduction in functional tumor
volume (FTV)15 from 10.50 to 6.26 cm3 (Fig. 2d–f). However, the
FES SUVmax showed an increase from 13.02 to 16.26. Surgical
pathology showed 2.1 cm residual of grade 2 IDC with Ki67 of <1%
(reduced from 20% at pre-treatment) and tumor cellularity of 5%
(pre-treatment cellularity not available).
DISCUSSION
ER+ breast cancer presents a unique set of challenges for
determining optimal treatment approaches. There is increased
Table 1. Patient and tumor characteristics
Patient Age Disease ER status HER 2 status (FISHa) Genetic assay score Tumor grade Stage Neoadjuvant therapy
1 61 ILC 95% HER2:CEP17= 1.1 HER2ave= 1.9 MammaPrint Low 2 ypT2N1a Letrozole
2 64 ILC >95% HER2:CEP17= 1.2 HER2ave= 3.2 MammaPrint Low 2 pT3N1a None
3 49 IDC 100% HER2:CEP17= 1.1 HER2ave= 2.0 MammaPrint High 2 ypT2N1mic Chemotherapy
w/o endocrine therapy
4 63 IDC 90% HER2:CEP17= 1.1 HER2ave= 1.9 Oncotype Low 2 pT2 None
5 33 IDC >95% HER2:CEP17= 2.0 HER2ave= 2.9 MammaPrint High 2 ypT2N1a Chemotherapy w/o
endocrine therapy
6 34 Unknown >90% HER2:CEP17= 1.3 HER2ave= 5.1 None 3 Denovo metastatic
unknown primary
None
aHER2 gene expression amplification by FISH:
Not amplified: HER2:CEP17 ratio <2.0 AND HER2ave <4.0 signals per cell
Equivocal: HER2:CEP17 ratio <2.0 AND HER2ave ≥4.0 and <6.0 signals per cell
Amplification: HER2:CEP17 ratio ≥2.0 OR HER2ave ≥6.0 signals per cell
Table 2. Summary of FES-dbPET imaging results
Patient SUVmax SULmax Tumor-normal
ratio
FES uptake volume
(cm3)
1 15.83 (V1) 9.32 (V1) 4.81 (V1) 15.72 (V1)
6.11 (V2)a 3.58 (V2)a 2.55(V2)a 0.37 (V2)a
2 22.42 15.65 4.3 35.63
3 13.02 (V1) 9.08 (V1) 8.04 (V1) 12.60 (V1)
16.26 (V2)b 11.61 (V2)b 8.74 (V2)b 6.97 (V2)b
4 7.44 5.67 2.52 0.22
5 No FES uptake detected due to the prior fertility preservation
treatment with tamoxifen
6 No FES uptake detected
aPatient FES-dbPET follow-up scan after 2 months of letrozole. V1=
baseline; V2= follow-up
bPatient FES-dbPET follow-up scan after 3 weeks of chemotherapy without
endocrine treatment. V1= baseline; V2= follow-up
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recognition that not all ER+ breast cancers benefit from
chemotherapy and that there may be a subset of ER+ breast
cancers that can be spared cytotoxic drugs and can be treated
effectively using endocrine therapies alone. In the neoadjuvant
treatment setting, imaging plays a critical role in non-invasively
assessing the response of the intact primary tumor to targeted
systemic therapies. Treatment-induced change in the primary
tumor can serve as a surrogate marker for the effect of treatment.
Thus, imaging evaluation of the primary tumor during treatment
can provide important prognostic and predictive information.16,17
Db-PET imaging with FES as a tracer presents a new opportunity
to develop an imaging marker for ER+ breast cancer. With the
high overall sensitivity and specificity to ER, this new breast
imaging tool may holistically inform the whole tumor ER
Fig. 1 Examples of FES uptake in >90% ER+/HER2− invasive lobular carcinomas (ILC, top panel) and invasive ductal carcinomas (IDC, bottom
panel). Top—a Patient #1—a 61-year-old female patient with grade 2 ILC in her right breast. MRI showed contrast enhancement spanning
6.7 cm. b FES-dbPET showed an SUVmax at 15.83 and total uptake volume at 15.72 cm
3. c Patient #2—a 64-year-old female patient with grade 2
ILC in her right breast. MRI showed an irregularly shaped mass with spiculated margins associating with non-mass enhancement of 5.3 cm. d
The corresponding FES-dbPET showed a SUVmax at 22.42 and total uptake volume at 35.63 cm
3. Bottom—e Patient #4—a 63-year-old female
patient with grade 2 IDC in her left breast. MRI showed a 0.9 cm confirmed IDC and a 1.3 cm irregular mass with posterior depth. f FES-dbPET
showed a SUVmax at 7.44 corresponding to the 0.9 cm anterior mass but missed the posterior mass that was close to the chest wall. g Patient
#5—a 33-year-old female patient with grade 2 IDC in her right breast. MRI showed an enhancing mass with spiculated margin spanning
3.4 cm. h The patient was treated with tomoxifen for fertility preservation and stopped 4 days prior to FES-dbPET imaging. The corresponding
FES-dbPET showed no FES uptake that was consistent with ER blockade
Fig. 2 Examples of FES-dbPET for assessing treatment response. Top patient #1 with ILC—a FES-dbPET imaging at baseline with a SUVmax at
15.83 and total uptake volume at 15.72 cm3. b FES-dbPET of the same patient after 2 months of treatment with letrozole showing a SUVmax at
6.11 and total uptake volume at 0.37 cm3. c DCE-MRI after 3 months of treatment with letrozole, confirming the favorable response with no
residual disease but with significant background enhancement. Bottom patient #3 with IDC—d A 49-year-old female patient with grade 2 IDC
in her left breast. FES-dbPET imaging at baseline showed a SUVmax at 13.02 and total uptake volume at 12.60 cm
3. e FES-dbPET of the same
patient after 3 weeks of treatment with chemotherapy without endocrine therapy had a SUVmax at 16.26 but a reduced total uptake volume at
6.97 cm3 (45% reduction). f, g DCE-MRI at baseline and after 3 weeks of treatment, confirming the tumor size reduction by 40%
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functionality and provide valuable information to guide therapy
selection. Herein, we report our effort to evaluate the FES-dbPET
technology for enabling a more precise characterization of ER+
primary breast tumor and its response to neoadjuvant treatment.
In this small cohort, we observed variation in FES uptake even
though all patients were >90% ER+/HER2− as determined by IHC
and FISH. Variability of FES binding was also observed in another
study with 91 ER+ breast cancer patients with an intraclass
correlation coefficient of 0.6.18 The FES uptake variation may be
attributed in part by the histologic characteristic of the breast
cancer. At high resolution, dbPET was able to capture the FES
uptake pattern in two ILC patients, showing a poorly circum-
scribed diffuse pattern (Fig. 1) that is consistent with the low
tumor cell density and lack of desmoplastic stromal reaction
characteristics.19 In contrary, the strong FES uptake in IDC was
focal and well-defined, reflecting the high cellularity structurally
similar phenotype.20
Imaging response to treatment was evaluated in two patients
who underwent neoadjuvant therapy—one with letrozole, and
one with chemotherapy. Letrozole is an aromatase inhibitor that
prevents the activation of the ER by inhibiting the conversion of
androgens to estrogens. Clinical studies21,22 have shown a clear
benefit of letrozole over tamoxifen in treating ER+ breast cancers
in postmenopausal women. In our case, we observed a reduction
of FES uptake in a postmenopausal patient with ILC after two
months of treatment, while surgical excision showed significant
residual ILC. Given this patient had a marked improvement on the
post-treatment MRI, these findings likely reflect that the patient
might have started with a significant burden of disease that was
unappreciated by currently available imaging techniques. Albeit
incomplete, the reduction in MRI size, Ki67, and FES uptake are all
consistent with response to therapy. An alternative explanation is
that the reduction in FES uptake reflects non-functional ER in the
remaining lobular disease, which could imply endocrine therapy
resistance. Future study is critical to understand the significance of
the change in FES uptake after endocrine therapy, particularly in
ILCs that are treated primarily with endocrine agents.
Another patient with IDC was treated with chemotherapy
without endocrine treatment. The FES SUVmax increased by 25%
after three weekly cycles of treatment, but the FES uptake volume
dropped by 31% and was confirmed by DCE-MRI. The partial
response to chemotherapy was reflected in surgical pathology,
which showed residual disease but low tumor cellularity. While
SUVmax is a well-accepted metric for tracer uptake in primary
tumors and metastatic diseases, it can be potentially biased with
high variance depending on the noise level of the image.23 At
high resolution, dbPET uses a smaller pixel size (0.5 mm vs.
3–5mm in whole-body PET/CT) that may contribute to more noise
and higher variance. In addition, SUVmax represents the maximum
value for a lesion based on a single voxel, it may not adequately
account for the binding of FES to the ER, and hence the overall ER
functionality. In a randomized study of FES-PET as a predictor of
response to neoadjuvent treatment in ER+ postmenopausal
women,24 there was no correlation between baseline FES SUVmax
and pathologic response in ER-rich breast cancer, suggesting
other tracer uptake metrics should also be considered in
conjunction with SUVmax. In this study, we examined maximum
SUV normalized by lean body mass (SUL), mean SUV (SUVmean)
and tumor-to-normal tissue ratio, but none of them were able to
describe the anatomical change observed by MRI. Future studies
will include the change of SUVmax from baseline, volumetric
measurement25 such as total uptake volume and textural
features26 that reflect tumor heterogeneity in conjunction with
SUVmax, SUL, SUVmean, and tumor-to-normal tissue ratio as
predictors of treatment response in a larger cohort.
The current version of the dbPET with the standard 200 mm
aperture on the scan bed has limited posterior sensitivity near the
chest wall. A new design described by O’Connor et al.27 has an
enlarged aperture (220 mm), a thinner chest resting area and a
flexible silicone sleeve to allow a significant gain of breast tissues
near the chest wall within the detector field of view. However, the
exclusion of the axillary lymph node remains a significant
limitation of this technology. Modification of the scan bed with
a larger flexible aperture, a new detector configuration with
angular coverage and an improved image reconstruction algo-
rithm may potentially mitigate the problem of the field of view
and provide accurate quantification of the nodal signal. Further
development in these areas is much needed.
In two patients, there was absence of FES uptake. One patient
received tamoxifen prior to imaging, and the other had an
unknown location of the primary breast tumor. Tamoxifen is a
selective estrogen receptor modulator that binds to the ER and
induces conformational changes28 that alter transcriptional
activity. Tamoxifen will, therefore, affect the FES uptake. Some
studies required the discontinuation of tamoxifen for 6–8 weeks
prior to FES-PET imaging.13,14 In our case, the absence of FES
uptake in patient #5 also reflects the specificity of FES binding to
the ER.
FES uptake was not detected in the final patient (#6) with the
unknown primary tumor that was occult from mammography and
MRI. Whether the absence of uptake on FES is due to the location
or size of the primary tumor, or whether this tumor is also occult
on FES-PET imaging is unknown.
In conclusion, this feasibility study demonstrates that FES-dbPET
imaging has potential as an imaging tool to characterize primary
ER+ breast cancer and to guide therapy selection. Limitations
include variations of FES uptake in different ER+ breast cancer
diseases and exclusion of posterior breast tissue near the chest
wall and the axillary regions. In evaluating response to treatment,
other uptake metrics adjunct to SUVmax may be considered to
describe the overall ER status before and after treatment. Further
studies involving larger numbers of patients are needed to
validate our initial observations.
METHODS
Ethics statement
Six patients with biopsy-confirmed >90% ER+/HER2− breast cancer were
recruited to participate in an imaging study with dbPET (MAMMI, General
Equipment and Medical Imaging SA (OncoVision), Valencia, Spain). The
dbPET imaging study was a HIPPA-compliant study protocol that was
reviewed by the institutional review board and approved by the
Committee of Human Research under the institution Human Research
Protection Program. The use of FES for human imaging was approved by
the Radioactive Drug Research Committee. A written informed consent
was provided by the patient to participate.
Patient characteristics
To limit patient’s radiation exposure, a separate whole-body FES-PET/CT
imaging was not performed. All patients underwent physical examination
for regional adenopathy and breast MRI. Patients with adenopathy
identified by clinical examination or ultrasound evaluation underwent
needle biopsy of the nodes. Patients with clinical stage III disease
underwent whole-body FDG-PET/CT or chest/abdomen pelvis CT. Staging
was obtained per requirements of additional clinical trials for some patients.
Other patients received a whole-body single photon emission tomography
(SPECT) with [99mTc] hydoxydiphosphonate for bone metastases.
DbPET imaging
DbPET was performed with a low dose of FES ranging 4.94–5.38mCi
(median, 4.99mCi) at 45 min post-injection. Patients were scanned in the
E.F. Jones et al.
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prone position with a single breast positioned down through the aperture
inside the detector ring, which can be translated axially to image the entire
breast from inferior to superior at approximately 15min per breast. FES
dose at the time of injection and time of imaging was recorded. A follow-
up dbPET scan was performed in two patients after 2 months of endocrine
treatment (patient #1) and three weekly cycles of chemotherapy without
endocrine treatment (patient #3). Same imaging procedure and tracer
dose was repeated as performed at baseline. DbPET images were
reconstructed in 3D using the manufacturer-provided maximum likelihood
expectation maximization (MLEM)29 algorithm with 16 iterations. All
images were corrected for attenuation through image segmentation,
scatter, and decay.30 Tumor volume-of-interest (VOI) encompassing the
entire abnormal tissue volume was calculated using an SUV cutoff of 2.5.
Subsequent analyses of tumor FES uptake were performed by (1)
calculating maximum and mean SUVs normalized by body weight (SUVmax,
SUVmean);
31 (2) maximum and mean SUVs normalized by lean body mass
(SULmax, SULmean); (3) examining the tumor-to-nontumor ratio by placing
VOIs on tumor and normal breast tissue within the field of view; and (4)
total FES uptake volume.
Reporting Summary
Further information on experimental design is available in the Nature
Research Reporting Summary linked to this article.
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